BIOFT Forms Strategic Partnership with TER Chemicals to Accelerate Global Expansion into Europe

- Strengthening collaboration following successful presentation at in-cosmetics Paris 2026     BIOFT, a specialized company in high-performance cosmetic ingredient R&D and finished product ODM solutions, today announced that it has entered into a strategic partnership with TER Chemicals Distribution Group (“TER Chemicals”), a globally recognized chemical distribution company with over a century of heritage. Through this partnership, BIOFT aims to accelerate its expansion into the European and broader global markets.   Founded in 1908 and headquartered in Hamburg, Germany, TER Chemicals has established itself as a key player in the global chemical industry. As of 2024, the group reported approximately EUR 920 million in annual revenue and employs over 1,100 professionals worldwide. Guided by a strong commitment to integrity and trust, TER Chemicals goes beyond traditional distribution by positioning itself as a “holistic partner,” offering integrated solutions encompassing logistics, formulation support, and product development.   Through this collaboration, BIOFT will gain access to TER Chemicals’ well-established European network, creating a powerful platform to introduce its differentiated bio-based ingredients to global markets.   The partnership will primarily focus on BIOFT’s flagship ingredient, Vegan PDRN, which aligns closely with the rapidly growing Clean Beauty and Sustainability trends across Europe. This next-generation ingredient combines plant-derived bioactive compounds—such as phenols and polyphenols—with the core benefits of PDRN, including skin regeneration and enhanced elasticity.   A key differentiator of BIOFT’s Vegan PDRN lies in its fully customized, order-made R&D capability. BIOFT selects optimal plant sources tailored to each client’s brand concept and desired skin benefits, offering an end-to-end solution from extraction to production of customized PDRN ingredients.   BIOFT’s technological capabilities have already been validated in the domestic market through successful collaborations with leading cosmetic brands.   The two companies recently held a joint presentation at in-cosmetics Paris 2026, marking a significant milestone that has led to deeper collaboration beyond a conventional supply relationship.   In addition, with the rising global popularity of K-beauty, interest in salmon-derived PDRN is also increasing. BIOFT is currently engaged in active discussions regarding the global supply of its high-purity salmon PDRN, further expanding its portfolio in the international market.   정현식 기자partnership expansion this partnership partnership will european network

2026.05.06. 20:26

DKSH and Kyowa Kirin Mark Major Milestone by Activating Partnership in Six Asia-Pacific Markets

  DKSH and Kyowa Kirin celebrate a pivotal moment with the initiation of the partnership in South Korea, Taiwan, Singapore, Thailand, Malaysia, Hong Kong and Macau from the beginning of Octo-ber. In close collaboration with Kyowa Kirin, DKSH will focus on providing end-to-end healthcare solutions, with an emphasis on improving patient access to healthcare.   Singapore, October 1, 2024 – DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consum-er health and medical device companies, and Kyowa Kirin, a Japan-based Global Specialty Pharmaceuti-cal Company, celebrate the activation of the recently announced partnership with a signing ceremony in Tokyo, Japan. The partnership will be initiated in South Korea, Taiwan, Singapore, Thailand, Malaysia, Hong Kong and Macau, starting on October 1, 2024.   Under this strategic partnership, DKSH will implement an alliance business model that delivers end-to end healthcare solutions prioritizing healthcare access to patients. The scope of the collaboration includes Kyowa Kirin’s established portfolio for all six markets as well as global brands such as Crysvita and Poteligeo for Hong Kong, Macau, Thailand, Malaysia, and Singapore. The partnership also includes the transition of Kyowa Kirin employees over to DKSH across these markets, ensuring strong process and knowledge continuity throughout the transition.     “Guided by our ‘Story for Vision 2030’, we have defined a plan to transform our Asia-Pacific (APAC) busi-ness to maximize patient access to our medicines and for more optimized and sustainable operations. This requires choosing the right partner to support our transformation journey. Recognizing DKSH’s deep expertise in nephrology, robust distribution networks, strong commercial capabilities, and an im-portant commitment to our employees we are confident that DKSH is the right partner,” stated Abdul Mullick, Ph.D., Chief International Business Officer (CIBO), Kyowa Kirin.   Bijay Singh, Global Head Business Unit Healthcare, Member of the Executive Committee, DKSH, added: “We are truly excited to be the strategic healthcare solution partner of Kyowa Kirin. The teams from both companies have worked closely in the past months to prepare for a seamless business transition. Tremendous work has gone into building the plans for transition of employees, regulatory requirements, supply chain integration, medical affairs, and commercial plans. I am very proud to see that the teams have collaborated with openness and trust to find the best way forward and overcome any challenges that came along the way. At DKSH, we believe that trust is foundational for all successful long-term partnerships. We look forward to a long and fruitful partnership, with a successful kick off starting in October 2024.” 강동현 기자 [email protected] activating partnership will partnership in healthcare solutions

2024.10.15. 22:21